[go: up one dir, main page]

AU2001263443A1 - F-protein epitope-based vaccine for respiratory syncytial virus infection - Google Patents

F-protein epitope-based vaccine for respiratory syncytial virus infection

Info

Publication number
AU2001263443A1
AU2001263443A1 AU2001263443A AU6344301A AU2001263443A1 AU 2001263443 A1 AU2001263443 A1 AU 2001263443A1 AU 2001263443 A AU2001263443 A AU 2001263443A AU 6344301 A AU6344301 A AU 6344301A AU 2001263443 A1 AU2001263443 A1 AU 2001263443A1
Authority
AU
Australia
Prior art keywords
virus infection
respiratory syncytial
syncytial virus
based vaccine
protein epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001263443A
Inventor
Mark S. Hanson
Scott Koenig
Joann Suzich
Nancy Ulbrandt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of AU2001263443A1 publication Critical patent/AU2001263443A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2001263443A 2000-05-25 2001-05-25 F-protein epitope-based vaccine for respiratory syncytial virus infection Abandoned AU2001263443A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20694600P 2000-05-25 2000-05-25
US60206946 2000-05-25
PCT/US2001/017022 WO2001089562A1 (en) 2000-05-25 2001-05-25 F-protein epitope-based vaccine for respiratory syncytial virus infection

Publications (1)

Publication Number Publication Date
AU2001263443A1 true AU2001263443A1 (en) 2001-12-03

Family

ID=22768618

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001263443A Abandoned AU2001263443A1 (en) 2000-05-25 2001-05-25 F-protein epitope-based vaccine for respiratory syncytial virus infection

Country Status (3)

Country Link
US (1) US20020018780A1 (en)
AU (1) AU2001263443A1 (en)
WO (1) WO2001089562A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289550A3 (en) * 2000-01-27 2012-02-15 MedImmune, LLC Ultra high affinity neutralizing antibodies
JP2003525061A (en) * 2000-03-01 2003-08-26 メディミューン，インコーポレイテッド High potency recombinant antibody and method for producing the same
US6855493B2 (en) * 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
JP2005533861A (en) * 2002-07-25 2005-11-10 メデュームン，インコーポレーテッド Therapies and prophylaxis of RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
AU2005286770A1 (en) * 2004-09-21 2006-03-30 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
AU2012202860B2 (en) * 2004-09-21 2015-04-02 Medlmmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
CA2585891A1 (en) * 2004-10-29 2006-05-11 Medimmune, Inc. Methods of preventing and treating rsv infections and related conditions
WO2008045252A2 (en) 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US8852608B2 (en) 2009-02-02 2014-10-07 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
US8778888B2 (en) * 2009-11-06 2014-07-15 The Board Of Trustees Of The Leland Stanford Junior University Cystine knot peptides binding to alpha IIb beta 3 integrins and methods of use
PL2950886T3 (en) 2013-02-01 2020-06-01 Medimmune, Llc Respiratory syncytial virus f protein epitopes
CN113322264B (en) 2013-03-14 2024-05-31 爱默蕾大学 Recombinant RSV with silent mutations, vaccines and methods relating thereto
CN105188748A (en) * 2013-04-08 2015-12-23 米迪缪尼有限公司 Vaccine composition and method of use
US11235050B2 (en) * 2015-10-29 2022-02-01 Emory University Chimeric RSV, immunogenic compositions, and methods of use
WO2018132516A1 (en) 2017-01-10 2018-07-19 Nodus Therapeutics Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
KR20200018483A (en) * 2017-06-14 2020-02-19 비로메틱스 아게 Cyclic Peptides for Defense Against Respiratory Syndrome Virus

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639853A (en) * 1987-09-29 1997-06-17 Praxis Biologics, Inc. Respiratory syncytial virus vaccines
GB9207479D0 (en) * 1992-04-06 1992-05-20 Scotgen Ltd Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man

Also Published As

Publication number Publication date
WO2001089562A1 (en) 2001-11-29
US20020018780A1 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
AU2001263443A1 (en) F-protein epitope-based vaccine for respiratory syncytial virus infection
EG24026A (en) Respiratory syncytial virus replication inhibitors
AU2002353378A1 (en) Vaccine for periodontal disease
HUP0201869A3 (en) Respiratory syncytial virus replication inhibitors
HUP0201789A3 (en) Respiratory syncytial virus replication inhibitors
AU2002229390A1 (en) Attenuated live vaccine
DE60038877D1 (en) COMBINATION VACCINE AGAINST STREPTOKKKUS PNEUMONIAE AND RESPIRATORY SYNCYTIAL VIRUS (RSV)
AU2002242935A1 (en) A process for the preparation of a non-toxic anthrax vaccine
AU2001238401A1 (en) Cold-adapted equine influenza viruses
AU2002322059A1 (en) Improved vaccination against anthrax
AU2001278337A1 (en) Respiratory syncytial virus vaccine
AU2001269640A1 (en) Vaccine against the influenza virus and method for producing said virus vaccine
AU2002230609A1 (en) Aerodynamically light vaccine for active pulmonary immunization
AU6964001A (en) Vaccine against the influenza virus and method for producing said virus vaccine
AU5918100A (en) Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
AU2001278323A1 (en) Modified sialic acid vaccines
AU4606000A (en) Vaccine for newcastle disease virus
AU2002236065A1 (en) Papillomavirus vaccines
AU2002223398A1 (en) A vaccine for influenza virus and its preparation
AU4994800A (en) Plant-derived antigens against respiratory syncytial virus
AU2001271909A1 (en) Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines
AU2001291202A1 (en) Avian pneumovirus vaccine
HK1089700A (en) Subunit vaccine against respiratory syncytial virus infection
AU2001266534A1 (en) Papillomavirus vaccine
AU2001251761A1 (en) Equine protozoal myeloencephalitis vaccine